当前位置: 首页 > 期刊 > 《新医学》 > 201712
编号:13606615
PTPN9在肝癌中的表达及临床意义(4)
http://www.100md.com 2017年12月1日 《新医学》 201712
     [22]Su F, Ren F, Rong Y, Wang Y, Geng Y, Wang Y, Feng M, Ju Y, Li Y, Zhao ZJ, Meng K, Chang Z.Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer. Breast Cancer Res,2012,14(2):R38.

    [23]Hung MH, Tai WT, Shiau CW, Chen KF.Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy. World J Gastroenterol,2014,20(41):15269-15274.

    [24]Sharma Y, Ahmad A, Bashir S, Elahi A, Khan F.Implication of protein tyrosine phosphatase SHP-1 in cancer-related signaling pathways. Future Oncol,2016,12(10):1287-1298.

    [25]Hong Y, Liang H, Uzair-Ur-Rehman, Wang Y, Zhang W, Zhou Y, Chen S, Yu M, Cui S, Liu M, Wang N, Ye C, Zhao C, Liu Y, Fan Q, Zhang CY, Sang J, Zen K, Chen X.miR-96 promotes cell proliferation, migration and invasion by targeting PTPN9 in breast cancer. Sci Rep,2016,6:37421.

    (收稿日期:2017-06-06)

    (本文編辑:杨江瑜), http://www.100md.com(李晓华 张英才 邓宜南 杨晓星 张琪 杨扬 周奇)
上一页1 2 3 4